| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 2,098 | $16.88 | $35,423.47 | -100% | |
| Mar 4, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Sell | 606 | $16.88 | $10,231.28 | -7.0% | |
| Mar 4, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Griffin Deborah A | Chief Accounting Officer | Sell | 4,107 | $16.88 | $69,339.71 | -77.9% | |
| Mar 1, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $128.43 | $26,971,214.67 | - | |
| Mar 1, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 3,200 | $25.00 | $80,000.00 | -5.8% | |
| Mar 1, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Tarriff Scott | CEO | Sell | 24,428 | $51.17 | $1,250,014.68 | -0.8% | |
| Mar 1, 2019 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 1,000 | $127.01 | $127,010.00 | -15.2% | |
| Mar 1, 2019 | HROW Harrow, Inc. | Kammer Robert J | Director | Sell | 10,000 | $6.91 | $69,100.00 | -1.1% | |
| Mar 1, 2019 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $33.48 | $33,480.00 | -100% | |
| Mar 1, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 7,500 | $24.99 | $187,425.00 | -4.3% | |
| Mar 1, 2019 | TLRY Tilray Brands, Inc. | Kennedy Brendan87 | President And CEO | Sell | 87,139 | $80.17 | $6,986,082.09 | -9.1% | |
| Mar 1, 2019 | AMRN Amarin Corp Plc\uk | Kalb Michael Wayne | SVP And CFO | Sell | 100,000 | $22.09 | $2,209,098.34 | -36.2% | |
| Mar 1, 2019 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 55,543 | $21.85 | $1,213,524.05 | -3.6% | |
| Mar 1, 2019 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | Sell | 3,043 | $58.11 | $176,819.11 | -4.1% | |
| Feb 28, 2019 | TLPH Talphera, Inc. | Hamel Lawrence G | Chief Development Officer | Buy | 3,682 | $2.81 | $10,346.42 | +5.0% | |
| Feb 28, 2019 | DVAX Dynavax Technologies Corp | Ostrach Michael S | Senior Vice President | Sell | 35,444 | $8.94 | $316,764.10 | -14.7% | |
| Feb 28, 2019 | ANIK Anika Therapeutics, Inc. | Darling Joseph G | President And Ceo; Director | Buy | 1,000 | $33.20 | $33,200.00 | +4.7% | |
| Feb 28, 2019 | DVAX Dynavax Technologies Corp | Coffman Robert | Senior Vice President | Sell | 63,202 | $9.03 | $570,714.06 | -27.8% | |
| Feb 28, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 200,000 | $126.73 | $25,345,016.80 | - | |
| Feb 28, 2019 | TLPH Talphera, Inc. | Dasu Badri N | Chief Engineering Officer | Buy | 9,206 | $2.81 | $25,868.86 | +8.8% | |
| Feb 28, 2019 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 27,231 | $20.72 | $564,171.86 | -46.6% | |
| Feb 28, 2019 | TLPH Talphera, Inc. | Asadorian Raffi | Chief Financial Officer | Buy | 3,647 | $2.81 | $10,248.07 | +3.0% | |
| Feb 28, 2019 | TLPH Talphera, Inc. | Palmer Pamela P | Chief Medical Officer | Buy | 840 | $2.81 | $2,360.40 | +0.2% | |
| Feb 28, 2019 | TLPH Talphera, Inc. | Angotti Vincent J.56 | Chief Executive Officer | Buy | 3,234 | $2.81 | $9,087.54 | +1.3% | |
| Feb 28, 2019 | DVAX Dynavax Technologies Corp | Johnson David Louis | Vice President | Sell | 20,765 | $9.03 | $187,507.95 | -14.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.